CDKN2A and melanoma: Future work to test the hypothesis that the combination of BRAF or NRAS oncogenes and p15/p16 loss is sufficient for centrosome overduplication to occur will necessitate the creation of new stable cell lines, derived from normal melanocytes, that harbor this combination of mutations but lack the other mutations that may be present in melanoma lines.